COVID-19 vaccination for children between 15-18, boosters for above 60 years and healthcare workers, announces PM Modi

-

Prime Minister Narendra Modi on Saturday said COVID-19 vaccination for children between the age of 15 to 18 years will begin from 3 January amid a steady rise in the cases of the highly contagious Omicron variant of COVID-19.

The prime minister also said precautionary doses will be given to healthcare and frontline workers from 10 January.

For those above 60 years with comorbidities, precaution doses will also be given from 10 January, said Modi.

Since the start of the year from 16 January till now, India has registered 141 crore vaccine doses, said the prime minister.

He further added that 61 percent of India's population has received both the COVID-19 doses, while 90 percent received single dose.

COVID-19 not over yet: PM urges everyone to follow COVID-19 guidelines

Modi assured citizens that all possible preparations are in order to tackle increasing infections. He listed the number of hospital beds, oxygen beds available, and vaccination progress.

"COVID-19 isn't past us yet. Being careful is very important," he said.

"Today, the nation has 18 lakh isolation beds, 5 lakh oxygen-supported beds, 1.4 lakh ICU beds, and 90,000 special beds for children. Today, we have over 3,000 functional PSA Oxygen plants and four lakh Oxygen cylinders have been provided to all states," he said.

The prime minister also urged people to follow COVID-19 appropriate behaviour. "In India, many people have been found to be infected with Omicron. I would urge all of you not to panic, be careful and alert. Wear the mask and wash hands regularly."

Highlighting the need to follow COVID-19 protocols like wearing masks, PM Modi said, "The experience of fighting the coronavirus global epidemic so far shows that following all the guidelines at the individual level is a great weapon to combat corona. And the second weapon is vaccination."



from Firstpost India Latest News https://ift.tt/3msoeUL
FP Staff

Comments

Post a Comment

Popular posts from this blog

Both COVID-19 vaccine doses needed for good protection against B16172 variant

-
It’s been a concerning few weeks in the UK, with the B16172 variant first taking hold and then spreading to become dominant. This more infectious form of the virus, initially identified in India, is what we’re now going to have to live with – unless it is out-competed by another variant in the future. Worryingly, experts had predicted that B16172 might be able to escape some of the effects of vaccines, which if true would threaten to derail the UK’s plans to finish lifting restrictions from the end of June. However, Public Health England (PHE) has looked at the ability of various variants to evade immunity and says that the UK’s vaccines remain effective against the variants circulating, including B16172. On the surface, this looks like good news. But delve a bit deeper, and things get more complicated, says Paul Hunter, professor of medicine at the University of East Anglia. PHE’s research found a little drop-off in protection against B16172 among people who were fully vaccinated.
Read more

New coronavirus variant emerge in India: How should our COVID response change?

-
Image
After genome sequencing of over 10,000 COVID-19 cases in India, researchers have discovered a new variant with two new mutations which may be better at evading the immune system. In 15-20 percent of samples from the Indian state of Maharashtra (the state accounting for 62 percent of cases in the country) a new, double mutation in key areas of the virus has been detected. These are now known as the E484Q and L452R mutations. What makes the variant different? Both these mutations are concerning because they are located in a key portion of the virus – the spike protein – that it uses to penetrate human cells. Spike proteins attach via a “receptor binding domain”, meaning the virus can attach to receptors in our cells. These new mutations include changes to the spike protein that make it a “better fit” for human cells. This means the virus can gain entry more easily and multiply faster. Given what we have seen with other similar mutations , it might also make it harder for our immu
Read more

Aditya L1 Mission: Spacecraft is nearing its final phase, says ISRO chief

-
Aditya L1 spacecraft is nearing its final phase, and manoeuvres to enter the L1 point are expected to be completed by January 7, 2024, according to ISRO Chairman S Somanath. “Aditya is on the way. I think it has reached almost its final phase,” the ISRO chief told PTI on the sidelines of an event organised at VSSC to commemorate the 60th year of the First Sounding Rocket Launch. Aditya L1, India’s first space-based mission to study the Sun, was successfully launched on September 2 from the Satish Dhawan Space Centre (SDSC) in Sriharikota. The spacecraft, after travelling about 1.5 million km from Earth over 125 days, is expected to be placed in a Halo orbit around the Lagrangian point L1, considered closest to the Sun. He said that the last preparations for the spacecraft’s entry into the L1 point are currently underway incrementally.”Possibly by January 7th, the final manoeuvres will be done for entering into the L1 point,” Somanath added. Among other tasks, it will capture and tr
Read more